- Adagene dosed the first patient in a Phase 1 trial combining its antibody muzastotug with Incyte (NasdaqGS:INCY) asset INCA33890 for microsatellite stable colorectal cancer.
- The early stage study introduces INCA33890 into a colorectal cancer combination regimen after prior updates on other parts of Incyte's pipeline.
- This initial patient dosing with muzastotug and INCA33890 gives investors another data point on how broad Incyte's immuno-oncology ambitions may be. This can be set against the rest of our findings on the stock. Our analysis turns up 2 warning signs for Incyte as well.
For a wider view of potential opportunities in related sectors, consider exploring other companies linked to AI infrastructure via 54 AI infrastructure stocks.
Incyte is a US biopharmaceutical group with a US$23.8b market cap that focuses on discovering and commercializing therapies across the US, Europe, Canada, and Japan. Pairing with Adagene on muzastotug and INCA33890 fits its broader push in immuno-oncology research collaborations.
2 things going right for Incyte that this headline doesn't cover.
For Incyte investors, this muzastotug combo is another test of the GI oncology plan, not a reset
The muzastotug and INCA33890 study nudges Incyte’s Narrative forward on one specific point. It adds another way to probe TGFβR2×PD 1 biology in microsatellite stable colorectal cancer, which ties directly to the GI oncology catalyst in the existing story. For investors tracking the shift toward a multi franchise model, this trial reinforces the idea that Incyte is trying to broaden its colorectal footprint rather than changing the central question. That question remains whether GI programs and other late stage assets can justify the higher R&D and deal related spending already visible in the recent net loss.
See how these catalysts shape Incyte's path to a $128 fair value.
The clearest marker to watch is how early safety and activity data from this Phase 1 muzastotug combination compare with the INCA33890 colorectal results presented at ESMO 2026 and with readouts from the ongoing NEXERA 303 Phase 3 trial. If signals from these studies line up over the next few years, the case that Incyte’s GI oncology strategy is on track strengthens. If they diverge or stall, the Narrative risk around GI spending and pipeline uncertainty comes to the foreground.
One more thing Incyte investors should check before moving on
Everything here looks at what Incyte is doing right now, but analyst projections carry the story out several years and point to a destination this article has not touched. See where analysts expect Incyte to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com